Overview
Plain-language guide
Discussed or marketed in research-only contexts for Growth hormone claims, Body-composition claims, Recovery claims. It is not approved for treating these uses.
It signals the pituitary gland to release more of the body’s own growth hormone. A hormone change alone does not prove muscle or recovery benefit.
Clinical mechanism
Activates the growth hormone-releasing hormone receptor; current marketed products require product-specific regulatory and quality review.
Applications
Human evidence
Validated human efficacy evidence is absent, limited or not independently replicated.
Tier 3Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Muscle & recovery profile
Each signal is scored independently from 0–5. There is no composite “best” score.
Evidence classes
What has been studied
- Physiologic effects on growth-hormone signaling have been examined.
What is not established
- Current grey-market claims for muscle gain, fat loss or recovery are not supported by robust modern trials.
Studied populations
- Historical endocrine research populations
Major limitations
- Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
- Findings from one population, formulation or indication should not be generalized to another.
Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.
Regulatory status
Unapproved / RUO. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.
Safety
Uncertain or Concerning
- Human safety data are incomplete
- Product identity, sterility and dose consistency may be unknown
Interactions
Combination data are sparse. Absence of documented interaction evidence is not evidence of compatibility.
Treatment pattern
No validated human dosing or cycling protocol exists.
Manufacturing and quality
RUO and grey-market products may not establish identity, net content, sterility, endotoxin control or cold-chain integrity.
Sponsor and development history
No current approved-product sponsor · Unapproved / grey-market context. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
- 01Primary regulatory record
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 02Clinical trial registry
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 03Peer-reviewed literature
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
Gaps and unverified claims
- No validated human dosing or cycling protocol exists.
- Long-term safety and product-quality consistency remain unresolved.
Last reviewed
August 5, 2026 · Primary-source check needed